The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
Abstract
The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence‐based medicine methodology. Sixty‐eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence‐based medicine review updates the field and highlights gaps for research. © 2011 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Self-citationLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Evidence-Based Medicine: How to Practice and Teach EBM
Satya-Murti, S. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.284.18.2382 · Cited by 1,643
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.65 · Cited by 1,487
Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Follett, K. A., Weaver, F. M., Stern, M., Hur, K., Harris, C. L., Luo, P., Marks, W. J., Rothlind, J., Sagher, O., Moy, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907083 · Cited by 1,355
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Goodwin, V. A., Richards, S. H., Taylor, R. S., Taylor, A. H., & Campbell, J. L. (2008) · Movement Disorders · doi:10.1002/mds.21922 · Cited by 922 · cited 17×
“Several publications have recently reviewed the challenges of assessing physical therapy as an intervention in PD.(111,112) All studies to date have been for symptomatic adjunctive therapy in PD patients who are at least H&Y stage 1.”
BackgroundInfluentialA Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citation
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationBalestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Self-citationQuantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker
Wang, Y., & Liu, T. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25358 · Cited by 878
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Long-term effects of exercise and physical therapy in people with Parkinson disease
Mak, M. K., Wong-Yu, I. S., Shen, X., & Chung, C. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.128 · Cited by 549
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Self-citationSignaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Virtual reality for rehabilitation in Parkinson's disease
Dockx, K., Bekkers, E. M., Van den Bergh, V., Ginis, P., Rochester, L., Hausdorff, J. M., Mirelman, A., & Nieuwboer, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010760.pub2 · Cited by 373
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Self-citationThe Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Self-citationFerreira, J. J., Lees, A., Rocha, J.-F., Poewe, W., Rascol, O., & Soares-da-Silva, P. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00336-1 · Cited by 294
Self-citationAntonini, A., Stoessl, A. J., Kleinman, L. S., Skalicky, A. M., Marshall, T. S., Sail, K. R., Onuk, K., & Odin, P. L. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1502165 · Cited by 282
Lei, C., Sunzi, K., Dai, F., Liu, X., Wang, Y., Zhang, B., He, L., & Ju, M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224819 · Cited by 270
Deep brain stimulation for Parkinson's disease
Hariz, M., & Blomstedt, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13541 · Cited by 256
Canadian guideline for Parkinson disease
Grimes, D., Fitzpatrick, M., Gordon, J., Miyasaki, J., Fon, E. A., Schlossmacher, M., Suchowersky, O., Rajput, A., Lafontaine, A. L., Mestre, T., et al. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.181504 · Cited by 173
Self-citationMindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI
Pickut, B. A., Van Hecke, W., Kerckhofs, E., Mariën, P., Vanneste, S., Cras, P., & Parizel, P. M. (2013) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2013.10.002 · Cited by 174
A clinical view on the development of technology‐based tools in managing Parkinson's disease
Maetzler, W., Klucken, J., & Horne, M. (2016) · Movement Disorders · doi:10.1002/mds.26673 · Cited by 162
Hirsch, M. A., van Wegen, E. E. H., Newman, M. A., & Heyn, P. C. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0112-1 · Cited by 134
New trends in advanced Parkinson disease stage therapy
Kolesárová, M., Franko, O., Kolesár, D., Gažová, A., & Kyselovič, J. (2023) · Česká a slovenská farmacie · doi:10.5817/csf2023-1-37 · Cited by 2
Metadata
- Authors
- Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2011-10
- Volume
- 26
- Issue
- S3
- Pages
- S2-41
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W4211223857
- Cited by
- 523
- References
- 116
- FWCI
- 23.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.